Since circulating FABP4 was consistently found to be raised in relation to liver disease progression [56,57,58,59,60,61,62,63] this might imply that fatty liver could contribute significantly more than SAT to FABP4 serum levels during MAFLD progression. Here, FABP4 is linked to liver disorder.